Advaxis announces master clinical trial agreement
March 2014
by  |  Email the author

SHARING OPTIONS:

PRINCETON, N.J.—Biotechnology company Advaxis Inc. has announced an expansion of its collaboration with the GRU Cancer Center at Georgia Regents University by way of a master clinical trial agreement to conduct four Phase 1/2 clinical trials. The trials will study ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer, Advaxis’ two lead immunotherapies. The trials will evaluate ADXS-HPV in patients with surgically treatable cervical cancer prior to surgery, the optimal dose of ADXS-HPV and PD-1 antibody in patients with recurrent or refractory cervical cancer and high dose, repeating cycles of the drug in recurrent or refractory cervical cancer. The trials will also look at ADXS-cHER2 in women with Her2/neu over-expressing breast cancer with measurable disease who have progressed after prior standard therapy. Dr. Samir Khleif, director of GRU Cancer Center, will supervise the trials.
Code:

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.